LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+31.45%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$854M
AUM Growth
+$854M
(+5.3%)
Cap. Flow
+$14.8M
Cap. Flow
% of AUM
1.73%
Top 10 Holdings %
Top 10 Hldgs %
56.07%
Holding
52
New
14
Increased
5
Reduced
13
Closed
12
Top Buys
| 1 |
Immunovant
IMVT
|
$55.9M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$17.4M |
| 3 |
Xenon Pharmaceuticals
XENE
|
$15.8M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
$14.7M |
| 5 |
Astria Therapeutics
ATXS
|
$12.9M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$25.8M |
| 2 |
Ventyx Biosciences
VTYX
|
$24.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$16.8M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$16.7M |
| 5 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$13.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
IDEAYA Biosciences
IDYA
$2.15B
| $70.9M | 8.3% | 3,900,000 -235,000 | -6% | -$4.27M |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $69.8M | 8.18% | 1,350,000 +50,000 | +4% | +$2.59M |
|
3
Cytokinetics
CYTK
$4.23B
| $68.7M | 8.05% | 1,500,000 -200,000 | -12% | -$9.16M |
|
|
4
Immunovant
IMVT
$2.56B
| $55.9M | 6.55% | +3,150,000 | New | +$55.9M |
|
|
ALLK
5
DELISTED
Allakos
ALLK
| $44.5M | 5.21% | 5,286,666 -650,000 | -11% | -$5.47M |
|
|
BCYC
6
Bicycle Therapeutics
BCYC
$511M
| $42.5M | 4.98% | 1,435,000 -565,000 | -28% | -$16.7M |
|
|
7
Xenon Pharmaceuticals
XENE
$2.98B
| $35.5M | 4.16% | 900,000 +400,000 | +80% | +$15.8M |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $32.1M | 3.76% | 1,500,000 | – | – |
|
|
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $29.5M | 3.45% | 150,000 | – | – |
|
10
Viridian Therapeutics
VRDN
$1.5B
| $29.2M | 3.42% | 1,000,000 | – | – |
|
11
Design Therapeutics
DSGN
$315M
| $28.7M | 3.36% | 2,797,501 | – | – |
|
12
Immunocore
IMCR
$1.62B
| $28.5M | 3.34% | 500,000 +150,000 | +43% | +$8.56M |
|
|
13
Sarepta Therapeutics
SRPT
$1.78B
| $28.5M | 3.34% | 220,000 -130,000 | -37% | -$16.8M |
|
14
ALX Oncology
ALXO
$62.7M
| $26.5M | 3.1% | 2,349,600 -621,752 | -21% | -$7.01M |
|
15
Dyne Therapeutics
DYN
$1.92B
| $24.9M | 2.92% | 2,150,000 -137,321 | -6% | -$1.59M |
|
16
Akero Therapeutics
AKRO
$3.74B
| $21.9M | 2.57% | 400,000 | – | – |
|
|
17
Ventyx Biosciences
VTYX
$171M
| $21.5M | 2.52% | 657,016 -740,664 | -53% | -$24.3M |
|
18
Arcutis Biotherapeutics
ARQT
$1.86B
| $20.7M | 2.43% | 1,400,000 -125,000 | -8% | -$1.85M |
|
|
DICE
19
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $20.6M | 2.41% | 660,000 -425,251 | -39% | -$13.3M |
|
|
20
Madrigal Pharmaceuticals
MDGL
$9.76B
| $17.4M | 2.04% | +60,000 | New | +$17.4M |
|
|
21
Rocket Pharmaceuticals
RCKT
$354M
| $14.7M | 1.72% | +750,000 | New | +$14.7M |
|
22
Fulcrum Therapeutics
FULC
$351M
| $14.6M | 1.71% | 2,000,000 +50,000 | +3% | +$364K |
|
|
23
Astria Therapeutics
ATXS
$349M
| $12.9M | 1.51% | +864,960 | New | +$12.9M |
|
24
Cogent Biosciences
COGT
$1.69B
| $12.7M | 1.49% | +1,100,000 | New | +$12.7M |
|
25
Geron
GERN
$893M
| $9.68M | 1.13% | 4,000,000 +2,000,000 | +100% | +$4.84M |
|